ESMO Open

ESMO Open is the online-only peer-reviewed open-access oncology journal of the European Society for Medical Oncology, founded in 2016 and published by Elsevier, with a 2025 impact factor of 10.6（ESMO Open）是欧洲肿瘤内科学会创办的纯在线同行评审开放获取肿瘤学期刊，创刊于 2016 年并由（Elsevier）出版，2025 年影响因子为 10.6。

Scope

• The journal publishes medical research and educational content from every discipline of oncology该刊发表涵盖肿瘤学各分支的医学研究与教育内容。
• Its central emphasis is innovative clinical and translational cancer research that links discovery with patient care其核心重点是连接科学发现与患者照护的创新临床及转化癌症研究。
• Coverage spans experimental, translational, diagnostic and therapeutic areas related to cancer研究范围横跨癌症相关的实验、转化、诊断与治疗领域。
• The journal seeks preclinical and early clinical data and encourages dialogue among academia, industry and clinical practice该刊关注临床前与早期临床数据并促进学术界、产业界与临床实践之间的交流。
• Formats include original articles, reviews, editorials, correspondence, brief reports, research letters and viewpoint articles文章形式包括原创论文、综述、社论、通信、简报、研究来信与观点文章。
• It also welcomes phase I trials, meta-analyses, diagnostic test presentations, conference reviews and ESMO position statements该刊还接收 I 期试验、荟萃分析、诊断检测展示、会议综述与 ESMO 立场声明。

History

• The European Society for Medical Oncology launched the journal in 2016 as an exclusively online open-access publication欧洲肿瘤内科学会于 2016 年创办该刊并从一开始采用纯在线开放获取模式。
• The journal initially carried the subtitle Cancer Horizons to express a broad international outlook该刊最初使用副标题（Cancer Horizons）以表达广泛的国际视野。
• Its subtitle later changed to Science for Optimal Cancer Care after growth in clinically relevant research and cooperation with the European Medicines Agency随着临床相关研究增长及与欧洲药品管理局合作加深其副标题改为（Science for Optimal Cancer Care）。
• Publishing responsibilities moved from the British Medical Journal to Elsevier during the journal's first eight years在创刊后的首个八年内出版职责由（British Medical Journal）转交（Elsevier）。
• The journal advanced from several years without an impact factor to 7.3 for 2022 and 10.6 for 2025该刊从创刊后数年尚无影响因子发展至 2022 年 7.3 与 2025 年 10.6。

Editors

• Hope S. Rugo of City of Hope Comprehensive Cancer Center is the Editor-in-Chief in 2026Hope S. Rugo 来自（City of Hope Comprehensive Cancer Center）并于 2026 年担任主编。
• Rugo's editorship continues the journal's focus on clinical and translational oncology across a global readershipRugo 任内延续面向全球读者的临床与转化肿瘤学重点。
• Giuseppe Curigliano took the Editor-in-Chief role in 2024 and set out to broaden the board and article formatsGiuseppe Curigliano 于 2024 年接任主编并提出扩大编委构成与文章形式。
• The earlier Editor-in-Chief team included Christoph Zielinski, Matthias Preusser and Anna Berghoff较早的主编团队包括 Christoph Zielinski、Matthias Preusser 与 Anna Berghoff。
• Associate editors and an international editorial board support the Editor-in-Chief in peer review and subject coverage副编辑与国际编委会协助主编开展同行评审并覆盖不同专业方向。